Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TAXOL AND VINORELBINE - A NEW ACTIVE COMBINATION FOR DISSEMINATED MALIGNANT-MELANOMA
Autore:
RETSAS S; MOHITH A; MACKENZIE H;
Indirizzi:
CHARING CROSS HOSP,DEPT MED ONCOL,MELANOMA UNIT LONDON W6 8RF ENGLAND
Titolo Testata:
Anti-cancer drugs
fascicolo: 2, volume: 7, anno: 1996,
pagine: 161 - 165
SICI:
0959-4973(1996)7:2<161:TAV-AN>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II;
Keywords:
DISSEMINATED; MALIGNANT; MELANOMA; TAXOL; TREATMENT; VINORELBINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
10
Recensione:
Indirizzi per estratti:
Citazione:
S. Retsas et al., "TAXOL AND VINORELBINE - A NEW ACTIVE COMBINATION FOR DISSEMINATED MALIGNANT-MELANOMA", Anti-cancer drugs, 7(2), 1996, pp. 161-165

Abstract

We evaluated the activity and toxicity of two sequences of taxol combined with vinorelbine in disseminated malignant melanoma, metastatic beyond regional lymph nodes, Fifteen previously untreated patients, nine males and six females (median age 56 years), were enlisted between May 1994 and February 1995. Eight patients received vinorelbine 30 mg/m(2) (maximum dose 50 mg) first, followed 24 h later by taxol 120 mg/m(2) (maximum dose 240 mg) infused over 3 h (the V/T sequence). Seven patients received the reverse (T/V) sequence. In 79 administered coursesthere were no anaphylactic episodes, the main toxicity being alopecia(WHO grade 3). Significant neutropenia, emesis or neuropathy was not observed in either schedule (WHO grades 0 or 1), Three major responses, all with the V/T sequence, were seen; one complete (CR) in nodal andcutaneous sites lasting 13 months and two partial (PR), omental, ascites in one and hepatic, splenic and nodal in the other, lasting 7 and 6 months, respectively. Clinically meaningful tumor regressions, not qualifying strictly for the criteria of major response, were observed in two additional patients in the T/V sequence, Taxol combined with vinorelbine is active against disseminated malignant melanoma, The importance of sequencing the two drugs remains to be determined with accrualof more patients into the study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 10:41:56